EyePoint, Inc. (EYPT) Stock Analysis

EyePoint halves workforce and ends Phase III trial early after endpoint miss

Tue, October 20, 2026 at 11:37 AM UTC 3 min read

EyePoint Pharmaceuticals (EYPT) has announced a significant reduction in its workforce by 50% and the premature termination of its Phase III clinical trial due to failing to meet primary endpoints. This decision raises concerns about the company's future growth prospects and financial stability, potentially impacting investor confidence. As a result, shareholders may need to reassess their positions in light of these developments and the implications for EyePoint's product pipeline.

Read full article →

EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO

Fri, September 4, 2026 at 10:13 AM UTC 2 min read

EyePoint Pharmaceuticals (EYPT) experienced a reduction in its fair value following recent analyst revisions related to the LUGANO trial results. This adjustment signals potential concerns about the company's future growth prospects and could impact investor sentiment. As analysts reassess the stock's valuation, investors may need to evaluate their positions in light of these developments.

Read full article →